American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID‐19 Pandemic: Version 3
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID‐19 Pandemic: Version 3
Authors
Keywords
-
Journal
Arthritis & Rheumatology
Volume 73, Issue 2, Pages -
Publisher
Wiley
Online
2020-12-05
DOI
10.1002/art.41596
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
- (2020) Manli Wang et al. CELL RESEARCH
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China
- (2020) Dawei Wang et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Baricitinib as potential treatment for 2019-nCoV acute respiratory disease
- (2020) Peter Richardson et al. LANCET
- COVID-19: combining antiviral and anti-inflammatory treatments
- (2020) Justin Stebbing et al. LANCET INFECTIOUS DISEASES
- A Novel Coronavirus from Patients with Pneumonia in China, 2019
- (2020) Na Zhu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hematological findings and complications of COVID ‐19
- (2020) Evangelos Terpos et al. AMERICAN JOURNAL OF HEMATOLOGY
- Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment
- (2020) Dan M. Roden et al. CIRCULATION
- Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients With Hypertension Hospitalized With COVID-19
- (2020) Peng Zhang et al. CIRCULATION RESEARCH
- In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
- (2020) Xueting Yao et al. CLINICAL INFECTIOUS DISEASES
- Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial
- (2020) Philippe Gautret et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis
- (2020) Jing Yang et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
- (2020) Chenguang Shen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area
- (2020) Safiya Richardson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Kidney disease is associated with in-hospital death of patients with COVID-19
- (2020) Yichun Cheng et al. KIDNEY INTERNATIONAL
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
- (2020) Fei Zhou et al. LANCET
- Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study
- (2020) Kelvin Kai-Wang To et al. LANCET INFECTIOUS DISEASES
- Coronaviruses and Immunosuppressed Patients: The Facts During the Third Epidemic
- (2020) Lorenzo D’Antiga LIVER TRANSPLANTATION
- Virological assessment of hospitalized patients with COVID-2019
- (2020) Roman Wölfel et al. NATURE
- Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies
- (2020) Jianjun Gao et al. BioScience Trends
- Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China
- (2020) Chaomin Wu et al. JAMA Internal Medicine
- Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?
- (2020) Lei Fang et al. Lancet Respiratory Medicine
- Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19)
- (2020) Nicholas J. Mercuro et al. JAMA Cardiology
- Assessment of QT Intervals in a Case Series of Patients With Coronavirus Disease 2019 (COVID-19) Infection Treated With Hydroxychloroquine Alone or in Combination With Azithromycin in an Intensive Care Unit
- (2020) Francis Bessière et al. JAMA Cardiology
- Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality
- (2020) Robert O. Bonow et al. JAMA Cardiology
- Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China
- (2020) Shaobo Shi et al. JAMA Cardiology
- Liver injury in COVID-19: management and challenges
- (2020) Chao Zhang et al. Lancet Gastroenterology & Hepatology
- Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol
- (2020) Niyada Naksuk et al. European Heart Journal-Acute Cardiovascular Care
- Renin-Angiotensin System Blockers and the COVID-19 Pandemic
- (2020) A.H. Jan Danser et al. HYPERTENSION
- Prolonged QT Interval in SARS-CoV-2 Infection: Prevalence and Prognosis
- (2020) Núria Farré et al. Journal of Clinical Medicine
- Worldwide expert agreement on updated recommendations for the treatment of systemic sclerosis
- (2019) Jeska de Vries-Bouwstra et al. JOURNAL OF RHEUMATOLOGY
- Association between hydroxychloroquine levels and disease activity in a predominantly Hispanic systemic lupus erythematosus cohort
- (2019) L Geraldino-Pardilla et al. LUPUS
- Factors predictive of serious infections over time in systemic lupus erythematosus patients: data from a multi-ethnic, multi-national, Latin American lupus cohort
- (2019) V R Pimentel-Quiroz et al. LUPUS
- Clinical and microbiological characteristics of the infections in patients treated with rituximab for autoimmune and/or malignant hematological disorders
- (2018) Jean-Jacques Tudesq et al. AUTOIMMUNITY REVIEWS
- Dose reduction of baricitinib in patients with rheumatoid arthritis achieving sustained disease control: results of a prospective study
- (2018) Tsutomu Takeuchi et al. ANNALS OF THE RHEUMATIC DISEASES
- Risk of Infection with Methotrexate Therapy in Inflammatory Diseases: A Systematic Review and Meta-Analysis
- (2018) Ammar Ibrahim et al. Journal of Clinical Medicine
- The emerging safety profile of JAK inhibitors in rheumatic disease
- (2017) Kevin L. Winthrop Nature Reviews Rheumatology
- Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy
- (2017) Kevin L. Winthrop et al. Arthritis & Rheumatology
- Treatment outcomes for patients with Middle Eastern Respiratory Syndrome Coronavirus (MERS CoV) infection at a coronavirus referral center in the Kingdom of Saudi Arabia
- (2016) Mohammed Al Ghamdi et al. BMC INFECTIOUS DISEASES
- Infection Risk and Safety of Corticosteroid Use
- (2016) Jameel Youssef et al. RHEUMATIC DISEASE CLINICS OF NORTH AMERICA
- Hydroxychloroquine Serum Concentrations and Flares of Systemic Lupus Erythematosus: A Longitudinal Cohort Analysis
- (2016) Chi Chiu Mok et al. ARTHRITIS CARE & RESEARCH
- Infections With Biologics in Rheumatoid Arthritis and Related Conditions: a Scoping Review of Serious or Hospitalized Infections in Observational Studies
- (2016) Jasvinder A. Singh Current Rheumatology Reports
- Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis
- (2015) A Richter et al. ANNALS OF THE RHEUMATIC DISEASES
- Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis
- (2015) Ronald F van Vollenhoven et al. ANNALS OF THE RHEUMATIC DISEASES
- Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis
- (2015) Jasvinder A Singh et al. LANCET
- Cardiovascular comorbidity in rheumatic diseases
- (2015) Michael T. Nurmohamed et al. Nature Reviews Rheumatology
- Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs
- (2015) Dimitrios A. Pappas et al. ARTHRITIS CARE & RESEARCH
- Systemic lupus erythematosus and pregnancy outcomes
- (2014) Erica Peart et al. CURRENT OPINION IN RHEUMATOLOGY
- Prevention and management of co-morbidities in SLE
- (2014) Tanmayee Bichile et al. PRESSE MEDICALE
- Appropriateness Criteria for Coronary Angiography in Angina: Reliability and Validity
- (2013) Harry Hemingway et al. ANNALS OF INTERNAL MEDICINE
- GRADE guidelines: 15. Going from evidence to recommendation—determinants of a recommendation's direction and strength
- (2013) Jeffrey C. Andrews et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations
- (2013) Jeff Andrews et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial
- (2013) Josef S Smolen et al. LANCET
- Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial
- (2013) Josef S Smolen et al. LANCET
- Do current arterial hypertension treatment guidelines apply to systemic lupus erythematosus patients? A critical appraisal
- (2013) Konstantinos Tselios et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Suppression of Coronavirus Replication by Cyclophilin Inhibitors
- (2013) Yoshikazu Tanaka et al. Viruses-Basel
- The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment
- (2012) J. Listing et al. RHEUMATOLOGY
- High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis
- (2011) K. Au et al. ANNALS OF THE RHEUMATIC DISEASES
- Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?
- (2011) A. Strangfeld et al. ANNALS OF THE RHEUMATIC DISEASES
- Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases
- (2011) Carlos G. Grijalva et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cyclosporin A inhibits the replication of diverse coronaviruses
- (2011) A. H. de Wilde et al. JOURNAL OF GENERAL VIROLOGY
- Utility of mTOR Inhibition in Hematologic Malignancies
- (2011) A. Younes et al. ONCOLOGIST
- Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly
- (2010) J. B. Galloway et al. RHEUMATOLOGY
- Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents
- (2009) Anja Strangfeld JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Diabetes and rheumatic diseases
- (2008) Todd W Burner et al. CURRENT OPINION IN RHEUMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation